[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![Sharad9Dubey Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::1077676619349712896.png) Sharad Dubey [@Sharad9Dubey](/creator/twitter/Sharad9Dubey) on x 45.2K followers
Created: 2025-07-18 07:03:21 UTC

NUVAMA ON DRL

CEO Mr Erez Israeli of Dr Reddy’s Laboratories (DRRD). Highlights: i) The company is optimistic on Semaglutide approval and first wave launch in Canada; this can be a good margin opportunity. ii) Abatacept development is on track while filing is likely by CY25-end. iii) Pembrolizumab is a large opportunity that opens beyond FY29. iv) The company has invested in assets, which can help to deliver ~25% EBITDA margins.


XXXXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1946103481166909860/c:line.svg)

**Related Topics**
[canada](/topic/canada)
[$drreddyns](/topic/$drreddyns)
[dr reddys](/topic/dr-reddys)

[Post Link](https://x.com/Sharad9Dubey/status/1946103481166909860)